Search Results
Jun 10, 2026, 02:22 ET Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
wide range of immune disorders, neurology and potentially endocrine conditions.3 The presentation will describe the inhibitory effect and PK/PD profile of Lu AG22515, including effects on membrane-bound and soluble CD40L, B-cell activation and differentiation, proinflammatory cytokine production
More news about: H. Lundbeck A/S
Jun 10, 2026, 02:19 ET Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
wide range of immune disorders, neurology and potentially endocrine conditions.3 The presentation will describe the inhibitory effect and PK/PD profile of Lu AG22515, including effects on membrane-bound and soluble CD40L, B-cell activation and differentiation, proinflammatory cytokine production
More news about: H. Lundbeck A/S
Jun 09, 2026, 21:00 ET Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China
tolerability of ATG-201 monotherapy and to determine its recommended Phase II dose (RP2D). Secondary objectives include evaluating the pharmacokinetic (PK) and pharmacodynamic (PD) profiles, immunogenicity, preliminary efficacy of ATG-201.Professor Zhanguo Li stated, "It is a great honor to
More news about: Antengene Corporation Limited
Jun 08, 2026, 08:31 ET MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential
mild-to-moderate and transient gastrointestinal adverse events and no treatment-related discontinuations or serious adverse events. Pharmacokinetic (PK) analysis demonstrated sustained exposure with dose-proportional behavior.DA-1726 produced a 6.1% reduction in body weight at Day 26 and a 9.1%
More news about: MetaVia Inc.
Jun 08, 2026, 04:30 ET 2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline
(T1/2) approximately 2 days, which supports a once-daily dosing regimen. Pharmacokinetics (PK) parameters after 4 weeks of sequential titration in MAD were consistent with SAD and exhibited linear PK characteristics.Overall manageable safety profile: IBI3032 showed a manageable safety
More news about: Innovent Biologics
Jun 05, 2026, 19:33 ET Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate
clinic-ready formulation and additional comparator studies will also be presented."These data are consistent with AMB-702's improved in vitro and PK profile, including superior target coverage over 24 hours, improved cell potency, flatter peak-to-trough and reduced plasma protein binding. The superiority
More news about: Ambrosia Biosciences
Jun 03, 2026, 10:00 ET HkeyBio New Platform Launch: AIH, PBC, and IgAN Model Matrix Empowers "One Drug, Multiple Screens" in Autoimmune New Drug R&D
translational value in the development of innovative biologics.In the future, the relevant platforms are expected to support:PK/PD evaluation.Humanized antibody research.Biomarker monitoring.Immunogenicity evaluation.Clinical dose prediction.IND-enabling
More news about: HKeyBio
Jun 02, 2026, 02:58 ET 微星科技 40 週年技術特展限時進駐松菸
1對戰，還配置了MSI Claw 掌機對戰專區，並引進多款最新強檔大作的現場實機試玩，包含《惡靈古堡九：安魂曲》與《索尼克賽車：交叉世界》系列等。展期更邀集重量級人氣 KOL 親臨現場，將於 6/5 (五) 夜間 18:00 後、以及 6/6 (六) 至 6/7 (日) 的下午與晚上時段，與現場玩家展開互動遊戲 PK 賽。AIoT 與AI PC (AI 未來實驗室)： 聚焦次世代頂尖算力與前瞻基礎建設，劃分為高階用戶端運算與智慧物聯網生態兩大核心。現場不僅集結最新世代 AI 筆電與桌機實機，更展示了
More news about: 微星科技
Jun 01, 2026, 08:00 ET SystImmune Reports Phase 1 Data for BL-M14D1 Demonstrating Promising Activity in Small-Cell Lung Cancer at ASCO
safety. Secondary endpoints include objective response rate (ORR) by RECIST 1.1 criteria, duration of response (DoR), disease control rate (DCR), and PK analysis.About BL-M14D1SystImmune is advancing a portfolio of next-generation antibody-drug conjugates (ADCs) built on its
More news about: SystImmune, Inc.
Jun 01, 2026, 07:30 ET Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
participants to characterize the safety, tolerability and pharmacokinetics of BHV-8100. Preliminary pharmacokinetic (PK) and safety data from the ongoing study:Confirmed PK profile is consistent with oral, once-daily dosingAchieved projected therapeutic exposuresDemonstrated
More news about: Biohaven Ltd.
May 31, 2026, 20:15 ET ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
(4/12), DCR 66.7% (8/12); nccRCC (n=6): ORR 33.3% (2/6), DCR 100.0% (6/6).4. Excellent PK/PD Characteristics(1) CS2009 demonstrated linear PK with a half-life of 6-9 days, supporting Q3W dosing. No significant accumulation was observed at Cycle 3. The incidence
More news about: CStone Pharmaceuticals
![PharmaLogic and Ratio Therapeutics Expand Manufacturing Collaboration to Support Clinical Development of [Ac-225]RTX-2358](https://mma.prnewswire.com/media/2700185/PharmaLogic_Holdings_Corp_Logo.jpg?w=300){kind=logo}
May 29, 2026, 08:00 ET PharmaLogic and Ratio Therapeutics Expand Manufacturing Collaboration to Support Clinical Development of [Ac-225]RTX-2358
NCT07156565). ATLAS is an open-label, seamless, Phase 1/2 clinical trial to evaluate the safety, tolerability, dosimetry, biodistribution, pharmacokinetics (PK), and anti-tumor activity of [Ac-225]RTX-2358 to treat patients with relapsed or refractory soft tissue sarcoma.The Phase 1 portion of the ATLAS
More news about: PharmaLogic Holdings Corp
![Ratio Therapeutics and PharmaLogic Expand Manufacturing Collaboration to Support Clinical Development of [Ac-225]RTX-2358](https://mma.prnewswire.com/media/2682145/Ratio_Therapeutics_Logo.jpg?w=300){kind=logo}
May 29, 2026, 08:00 ET Ratio Therapeutics and PharmaLogic Expand Manufacturing Collaboration to Support Clinical Development of [Ac-225]RTX-2358
NCT07156565). ATLAS is an open-label, seamless, Phase 1/2 clinical trial to evaluate the safety, tolerability, dosimetry, biodistribution, pharmacokinetics (PK), and anti-tumor activity of [Ac-225]RTX-2358 to treat patients with relapsed or refractory soft tissue sarcoma.The Phase 1 portion of the ATLAS
More news about: Ratio Therapeutics Inc.
May 27, 2026, 09:31 ET Sensorium Therapeutics to Present SNTX-2643 Mechanistic Data and Phase 1a Study Design at ASCP 2026
double-blind, placebo-controlled, and open-label (food-effect cohort) clinical study designed to characterize the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profile of SNTX-2643 in healthy adult volunteers following single-dose administration, and to inform the design of subsequent
More news about: Sensorium Therapeutics
May 27, 2026, 08:00 ET From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug Discovery
Assay enablement, protein construct quality, target modulation, in vivo efficacy, therapeutic index, scaffold-specific toxicity, DDI risk, cross-species PK, early CMC considerations, and nomination criteria can all influence program decisions.In this context, integration is less about placing multiple
More news about: Viva Biotech
May 27, 2026, 08:00 ET From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug Discovery
Assay enablement, protein construct quality, target modulation, in vivo efficacy, therapeutic index, scaffold-specific toxicity, DDI risk, cross-species PK, early CMC considerations, and nomination criteria can all influence program decisions.In this context, integration is less about placing multiple
More news about: Viva Biotech
May 27, 2026, 07:00 ET BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
progressive GBM and other high-grade gliomas. The objective is to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy.The Phase 2a expansion part of the trial is planned to include additional indications, including newly diagnosed
More news about: BioLineRx Ltd.
May 26, 2026, 12:33 ET Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery
New co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven human pharmacokinetic (PK) projection and integrated compound management —enabling scientists to make lead-optimization-quality decisions starting in hit identificationBOSTON,
More news about: Inductive Bio, Inc.
May 26, 2026, 09:26 ET At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)
UNLOXCYT is 1,200 mg as an intravenous infusion over 60 minutes every 3 weeks.UNLOXCYT (cosibelimab-ipdl) was approved at 1,200 mg Q3W because PK/PD modeling showed it provides similar overall exposure and PD-L1 receptor coverage as the trial regimen of 800 mg Q2W. Since checkpoint inhibitors have
More news about: Sun Pharma
May 26, 2026, 08:30 ET Deepening Focus on Autoimmune Diseases, Empowering AI-Driven Drug Discovery
clinical translation success rates.Integrated evaluation services include:Pharmacodynamics (PD)Pharmacokinetics (PK)Preliminary toxicologyMultiple endpoints can be evaluated within the same NHP model, enabling effective cost control while improving
More news about: HKeyBio
May 22, 2026, 07:00 ET AVISTA HEALTHCARE PARTNERS SIGNS DEFINITIVE AGREEMENT TO ACQUIRE SANOTACT GROUP
experience and track record in consumer healthcare and the wider consumer space. This includes: Cooper Consumer Health, Vision Healthcare, Omega Pharma, TOCG, PK Consumer Health and Fagron amongst others. For more information, visit
More news about: Avista Healthcare Partners
May 22, 2026, 07:00 ET BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
progressive GBM and other high-grade gliomas. The primary objective is to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy. Updates to the Phase 1/2a trial are anticipated during H2 2026, with full results on the dose escalation part expected in
More news about: BioLineRx Ltd.; Hemispherian AS
May 21, 2026, 17:00 ET Accent Therapeutics to Present Trial in Progress Poster for Phase 1/2 Study of ATX-295 at the 2026 American Society of Clinical Oncology Annual Meeting
include evaluation of the safety and tolerability of ATX-295 and determination of the RP2D. Secondary endpoints include assessment of pharmacokinetics (PK), pharmacodynamic (PD) effects, and preliminary antitumor activity. The Phase 1/2 study is currently open and actively enrolling patients.Details
More news about: Accent Therapeutics
May 20, 2026, 10:00 ET Sanyou Bio Launches SAI-DA 1.0, the AI-Drug Accelerator
dockingEpitope predictionAffinity optimizationImmunogenicity optimizationSpecificity predictionPharmacokinetics (PK) predictionEach algorithm has been refined and iteratively optimized through extensive real-world molecular discovery and PCC development
More news about: Sanyou Bio
May 19, 2026, 07:00 ET BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts
progressive GBM and other high-grade gliomas. The primary objective is to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy. Updates to the Phase 1/2a trial are anticipated during H2 2026, with full results on the dose escalation part expected in
More news about: BioLineRx Ltd.; Hemispherian AS